Mr. Finley is an experienced financial executive, having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal Chief Financial Officer (CFO) and an independent investment banker. Prior to joining Palisade Bio (formerly Leading BioSciences) as the company’s CFO, Mr. Finley was the Chief Executive Officer, President and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was a Principal and CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as Executive Vice President and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. Mr. Finley began his business career as a tax specialist with Deloitte & Haskins and Sells (now Deloitte LLP), and later was co-owner of Mitchell Finley & Company, a full-service accounting firm.

Mr. Finley earned a Bachelor’s degree in Business Administration from Boise State University and a Master’s degree in Taxation from the University of Denver.

Dr. Mitch Jones is an accomplished physician and executive with extensive experience in the development of innovative therapeutics for inflammatory and fibrotic diseases. As Chief Medical Officer at Palisade Bio, Dr. Jones oversees all clinical development programs, regulatory strategies, and medical affairs, ensuring the advancement of the company’s pipeline in inflammatory, autoimmune and fibrotic disease.

Dr. Jones has a distinguished track record of advancing innovative therapies from translational research through clinical development and achieving regulatory approvals. He most recently served as Vice President of Corporate Development & Strategy at Chemomab Therapeutics, where he directed corporate strategy, program development, and strategic partnerships. His efforts were instrumental in advancing Chemomab’s clinical-stage programs and supporting the company’s financing and M&A activities.

Prior to Chemomab, Dr. Jones held key leadership roles at Finch Therapeutics and Biora Therapeutics (formerly Progenity). At Finch Therapeutics, he was Vice President of Clinical Discovery and Development, contributing to the company’s IPO and the early clinical development of novel therapeutics for IBD, chronic hepatitis B, and solid tumor immunotherapy. At Biora Therapeutics, he served as Vice President of Innovation and Clinical Translational Development, where he lead the development of the company’s technology platforms including Navicap™ and Biojet™, executed early clinical development and proof of efficacy studies, created strategic roadmaps and played a pivotal role in securing $125 million in venture financing and leading the company through its IPO. His early role within the company was building the GI therapeutics division as Vice President of Translational and Clinical Development.

Dr. Jones founded Interface Therapeutics, where he developed a novel sampling platform for multi-omics analysis of GI tract samples, leading to the discovery of locally acting therapeutics for IBD. Interface Therapeutics was later acquired by Biora Therapeutics. Earlier in his career, he founded Micropharma, where he developed the FDA-approved product LRC™, now sold globally by Chr. Hansen, and achieved regulatory approvals for microbiome-based therapeutics for metabolic and inflammatory diseases.

Dr. Jones is an inventor on nearly 200 patents and has authored numerous scientific publications. He holds MD and PhD degrees.

Mr. Willie has served as Senior Vice President, Finance and Corporate Controller of Palisade Bio since February of 2023 and previously served as Vice President, Finance and Corporate Controller. Prior to joining Palisade Bio, Mr. Willie held various senior roles at PricewaterhouseCoopers, LLP where he provided key assurance services to clinical-stage biotechnology companies as they navigated the complexities of international collaborations, clinical trials, and follow-on offerings.

Mr. Willie earned a Master’s degree in Accountancy and Bachelor’s degree in Accounting from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

 Dr. Heyer is an accomplished leader in Translational Science, Translational Medicine, and Clinical Research with over two decades of experience in the pharmaceutical industry. Throughout his career he has played a pivotal role in the successful development and strategic management of multiple clinical drug programs including: FOTIVDA^® (tivozanib), a next-generation VEGFR TKI approved by the FDA in March 2021 for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC); Ficlatuzumab which is a potent, humanized IgG1 monoclonal antibody that targets HGF and is now tested in Phase 3 for HPV negative R/M HNSCC; CP101 which is a Phase 3, investigational, microbiome candidate in recurrent CDI; FN211 which is in Phase 1 for Autism Spectrum Disorder; and DCSZ11/DCBY02 fully humanized anti-CD93 antibodies regulating vascular normalization. In addition, Dr. Heyer worked on various preclinical molecules (i.e PDE4A inhibitor MEM1414) for neurodegeneration and Asthma. His contributions in drug development to disease modeling, gene expression profiling, histology, NGS and Translational Research have been documented in publications, presentations, patents and regulatory filings.

Dr. Heyer received his postdoctoral training at Albert Einstein College of Medicine in Human Genetics following receipt of his Ph.D. in Human Genetics from Julius Maximillians University in Wuerzburg Germany.